Ascentage Pharma Group International Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Ascentage Pharma Group International has been growing earnings at an average annual rate of 10.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 73.2% per year.
Información clave
10.4%
Tasa de crecimiento de los beneficios
29.5%
Tasa de crecimiento del BPA
Crecimiento de la industria Biotechs | 11.0% |
Tasa de crecimiento de los ingresos | 73.2% |
Rentabilidad financiera | -46.4% |
Margen neto | -39.9% |
Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up
Sep 04Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt
Aug 26Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up
Jun 18Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year
May 03Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge
Mar 30Are Investors Undervaluing Ascentage Pharma Group International (HKG:6855) By 40%?
Feb 17There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Dec 20Ascentage Pharma Group International (HKG:6855) Is Making Moderate Use Of Debt
Oct 28Some Analysts Just Cut Their Ascentage Pharma Group International (HKG:6855) Estimates
Aug 27There's Reason For Concern Over Ascentage Pharma Group International's (HKG:6855) Price
Aug 23Ascentage Pharma Group International (HKG:6855) Is Carrying A Fair Bit Of Debt
Jun 19Ascentage Pharma Group International (HKG:6855) Has Debt But No Earnings; Should You Worry?
Dec 04Is Ascentage Pharma Group International (HKG:6855) A Risky Investment?
Aug 30Does Ascentage Pharma Group International (HKG:6855) Have A Healthy Balance Sheet?
Oct 04Desglose de ingresos y gastos
Cómo gana y gasta dinero Ascentage Pharma Group International. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
---|---|---|---|---|
30 Jun 24 | 903 | -360 | 378 | 841 |
31 Mar 24 | 563 | -643 | 377 | 774 |
31 Dec 23 | 222 | -926 | 376 | 707 |
30 Sep 23 | 239 | -902 | 363 | 709 |
30 Jun 23 | 257 | -879 | 349 | 712 |
31 Mar 23 | 233 | -881 | 339 | 727 |
31 Dec 22 | 210 | -883 | 328 | 743 |
30 Sep 22 | 160 | -848 | 299 | 767 |
30 Jun 22 | 111 | -812 | 270 | 790 |
31 Mar 22 | 69 | -797 | 231 | 778 |
31 Dec 21 | 28 | -782 | 191 | 766 |
30 Sep 21 | 25 | -759 | 167 | 699 |
30 Jun 21 | 23 | -735 | 143 | 631 |
31 Mar 21 | 18 | -706 | 137 | 598 |
31 Dec 20 | 12 | -678 | 130 | 565 |
30 Sep 20 | 14 | -922 | 146 | 540 |
30 Jun 20 | 15 | -1,167 | 162 | 516 |
31 Mar 20 | 15 | -1,324 | 162 | 490 |
31 Dec 19 | 15 | -1,481 | 162 | 464 |
30 Sep 19 | 11 | -1,171 | 133 | 418 |
30 Jun 19 | 7 | -862 | 104 | 372 |
31 Mar 19 | 7 | -604 | 97 | 311 |
31 Dec 18 | 7 | -345 | 90 | 250 |
31 Dec 17 | 6 | -119 | 26 | 119 |
31 Dec 16 | 8 | -108 | 22 | 103 |
Ingresos de calidad: 6855 is currently unprofitable.
Margen de beneficios creciente: 6855 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 6855 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.4% per year.
Acelerando crecimiento: Unable to compare 6855's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: 6855 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).
Rentabilidad financiera
Alta ROE: 6855 has a negative Return on Equity (-46.43%), as it is currently unprofitable.